menu search

NKTR / Nektar Therapeutics (NKTR) Q3 2022 Earnings Call Transcript

Nektar Therapeutics (NKTR) Q3 2022 Earnings Call Transcript
Nektar Therapeutics (NASDAQ:NKTR ) Q3 2022 Earnings Conference Call November 3, 2022 5:00 PM ET Company Participants Vivian Wu - Director, Investor Relations and Corporate Affairs Howard Robin - President and Chief Executive Officer Brian Kotzin - Chief Medical Officer Jonathan Zalevsky - Chief Research and Development Officer Jillian Thomsen - Chief Financial Officer Conference Call Participants Chris Shibutani - Goldman Sachs Roger Song - Jefferies Group LLC Jessica Fye - JPMorgan Chase & Co. Greg Harrison - Bank of America Merrill Lynch Andy Hsieh - William Blair & Company Operator Good day, and thank you for standing by. Welcome to the Nektar Therapeutics Third Quarter 2022 Financial Results Conference Call. Read More
Posted: Nov 3 2022, 23:15
Author Name: Seeking Alpha
Views: 102498

NKTR News  

Nektar (NKTR), Cellular Biomedicine Join for Lung Cancer Studies

By Zacks Investment Research
September 28, 2023

Nektar (NKTR), Cellular Biomedicine Join for Lung Cancer Studies

Nektar (NKTR) enters into a deal with Cellular Biomedicine Group to develop NKTR-255 in combination with C-TIL05 to treat advanced NSCLC. more_horizontal

Nektar (NKTR) Up on Positive New Data From Eczema Study

By Zacks Investment Research
September 14, 2023

Nektar (NKTR) Up on Positive New Data From Eczema Study

Nektar (NKTR) gains on positive new data for its pipeline candidate, rezpegaldesleukin, evaluated from an early-stage study for treating atopic dermat more_horizontal

Nektar (NKTR) Stock Surges 75% in a Week: Here's Why

By Zacks Investment Research
August 14, 2023

Nektar (NKTR) Stock Surges 75% in a Week: Here's Why

Nektar's (NKTR) shares rally almost 75% in a week on corrected efficacy data for rezpeg studies, earlier miscalculated by Eli Lilly. more_horizontal

Nektar Therapeutics (NKTR) Q2 Loss Narrows, Sales Miss

By Zacks Investment Research
August 9, 2023

Nektar Therapeutics (NKTR) Q2 Loss Narrows, Sales Miss

Nektar (NKTR) incurs a narrower-than-expected second-quarter loss but misses on revenues. more_horizontal

Nektar Therapeutics (NKTR) Q2 2023 Earnings Call Transcript

By Seeking Alpha
August 8, 2023

Nektar Therapeutics (NKTR) Q2 2023 Earnings Call Transcript

Nektar Therapeutics (NASDAQ:NKTR ) Q2 2023 Earnings Conference Call August 8, 2023 5:00 PM ET Company Participants Vivian Wu - Director, Investor Rela more_horizontal

Nektar to Announce Financial Results for the Second Quarter 2023 on Tuesday, August 8, 2023, After Close of U.S.-Based Financial Markets

By PRNewsWire
August 1, 2023

Nektar to Announce Financial Results for the Second Quarter 2023 on Tuesday, August 8, 2023, After Close of U.S.-Based Financial Markets

SAN FRANCISCO , Aug. 1, 2023 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter 2023 on Tue more_horizontal

Nektar Therapeutics to Participate in Fireside Chat at the Goldman Sachs 44th Annual Global Healthcare Conference

By PRNewsWire
June 12, 2023

Nektar Therapeutics to Participate in Fireside Chat at the Goldman Sachs 44th Annual Global Healthcare Conference

SAN FRANCISCO , June 12, 2023 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) senior management is scheduled to participate in a virtual fireside more_horizontal

Nektar Therapeutics (NKTR) Q1 2023 Earnings Call Transcript

By Seeking Alpha
May 9, 2023

Nektar Therapeutics (NKTR) Q1 2023 Earnings Call Transcript

Nektar Therapeutics (NASDAQ:NKTR ) Q1 2023 Earnings Conference Call May 9, 2023 5:00 PM ET Company Participants Vivian Wu - Investor Relations Howard more_horizontal


Search within

Pages Search Results: